Joshua Schimmer
Stock Analyst at Cantor Fitzgerald
(1.38)
# 3,595
Out of 5,093 analysts
23
Total ratings
56.25%
Success rate
-6.96%
Average return
Main Sectors:
Stocks Rated by Joshua Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $2.50 | +1,900.00% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $65.40 | -23.55% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $87.09 | +5.64% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $71.30 | -71.95% | 1 | Mar 31, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $155.02 | -16.14% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $19.66 | +154.32% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $30.43 | -17.84% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $3.36 | +2,132.14% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $90 → $100 | $53.74 | +86.08% | 1 | Mar 1, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | n/a | $692.58 | - | 2 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $95.16 | -10.68% | 3 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.50
Upside: +1,900.00%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $65.40
Upside: -23.55%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $87.09
Upside: +5.64%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $71.30
Upside: -71.95%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $155.02
Upside: -16.14%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $19.66
Upside: +154.32%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $30.43
Upside: -17.84%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $3.36
Upside: +2,132.14%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90 → $100
Current: $53.74
Upside: +86.08%
Regeneron Pharmaceuticals
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $692.58
Upside: -
May 31, 2018
Assumes: Overweight
Price Target: $85
Current: $95.16
Upside: -10.68%